The case of tumour necrosis factor-α inhibitors in the treatment of rheumatoid arthritis
- Jan SørensenAffiliated withCentre for Applied Health Services Research and Technology Assessment (CAST), University of Southern Denmark Email author
- , Lis S. AndersenAffiliated withKing Christian X’s Rheumatology Hospital
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Treatment with tumour necrosis factor (TNF)-α inhibitors offers promising new opportunities to improve the health-related QOL of patients with rheumatoid arthritis (RA) in Denmark. As of September 2003, two such compounds — infliximab and etanercept — were registered for use by patients with RA. These drugs have shown the ability to reduce disease activity and to slow down or halt the development of new joint damage in otherwise treatment-resistant patients with RA. The acquisition cost of the drugs is high, with 1 year of treatment costing €9000–12 000 per patient.
Objective: The aim of this study was to assess the potential impact on the Danish healthcare budget of prescribing infliximab or etanercept to patients with RA.
Method: Two treatment implementation scenarios were investigated. In the progressive scenario, all patients newly diagnosed with RA were offered TNFα inhibitors as the drug of first choice. In the modest scenario, only patients with insufficient disease suppression by conventional therapy with disease-modifying anti-rheumatic drugs (DMARDs) were offered TNFα inhibitor therapy. The budget impact analysis, which was part of a Danish health technology assessment of TNFα inhibitors, focused on the number of patients offered treatment during a 5-year period and resource use related to drug and staff costs. Simple sensitivity analyses assessed the consequences of changing the drug dosage, the number of patients offered treatment and the rate of treatment cessation.
Results: The results suggested that both implementation strategies would impose additional costs per year on the Danish healthcare service, in the range of €67–188 million for the progressive scenario and €17–49 million for the modest scenario (price level August 2002). These costs represent between half and up to five times the amount currently used on treating patients with RA.
Conclusion: This analysis suggests that the introduction of TNFα inhibitors into the treatment regimen of patients with RA could pose a considerable financial burden on the Danish healthcare system.
- The case of tumour necrosis factor-α inhibitors in the treatment of rheumatoid arthritis
Volume 23, Issue 3 , pp 289-298
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors